Drug Type Fusion protein |
Synonyms Anticancer protein(Adamed), ONCO-3CLA project(Adamed), AD-051.4 |
Target |
Action agonists, inhibitors |
Mechanism DR4 agonists(Tumor necrosis factor receptor superfamily member 10A agonists), DR5 agonists(Tumor necrosis factor receptor superfamily member 10B agonists), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | Poland | 10 Apr 2013 | |
Hematologic Neoplasms | Discovery | Poland | 06 Jun 2019 |